A new study published in the International Journal of Molecular Sciences by researchers from the Georgia Institute of Cannabis Research at Augusta University found that inhaling cannabidiol (CBD) before glioblastoma tumors were established significantly slowed tumor progression in an animal model and altered key biological markers tied to aggressive cancer behavior.

Glioblastoma is one of the deadliest forms of brain cancer, known for rapid growth, resistance to treatment, and frequent relapse. Standard therapies often provide only limited survival benefits. In this study, researchers explored a novel approach: whether early exposure to CBD could “prime” the body’s immune and molecular environment in a way that makes it less hospitable to tumor growth.

To test this, C57BL/6 mice were given inhaled CBD for either three days or 14 days prior to the surgical implantation of glioblastoma cells into the brain. A control group received a placebo instead. After tumor implantation, researchers measured tumor growth and analyzed several biomarkers associated with tumor aggressiveness and immune suppression, including IDO, PD-L1, MGMT, and Ki67.

The results were striking. Mice that received 14 days of CBD pretreatment had significantly smaller tumor burdens compared to both the placebo group and the group that received CBD for only three days. This longer exposure to CBD was also linked to reduced expression of IDO and PD-L1, two immune checkpoint markers that tumors often use to evade the immune system. In addition, the CBD-pretreated mice showed lower levels of MGMT and Ki67, biomarkers associated with tumor growth, repair capacity, and proliferation.

According to the researchers, these combined changes point to a less aggressive tumor phenotype and suggest that prolonged CBD exposure before tumor development may shift the tumor microenvironment into a more anti-tumor state. In other words, CBD did not simply act on the tumor after it formed, but appeared to influence the body’s underlying biological landscape in a way that made it harder for the cancer to thrive.

The study is the first to examine the concept of CBD pretreatment prior to tumor establishment in a glioblastoma model, introducing what the researchers describe as a potential immune-modulatory strategy for improving disease control and reducing the likelihood of relapse.

While the findings are limited to animal models and further research is needed to determine whether similar effects occur in humans, the results suggest a new avenue for exploring how cannabinoids may play a role not just in symptom management, but in influencing the biological conditions that affect cancer progression.